Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Neogene","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","amount":"$110.0 million","upfrontCash":"Undisclosed","newsHeadline":"Neogene Therapeutics Raises $110 Million Series A Financing to Develop Next-Generation Neo-Antigen TCR Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Neogene","sponsor":"Twist Bioscience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Twist Bioscience and Neogene Announce Broad Strategic Partnership for Next Generation Personalized T Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"Neogene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neogene Therapeutics Announces Approval of Clinical Trial Application for its First Phase 1 Trial of Novel, Fully-Individualized TCR Therapy to Treat Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Neogene","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$320.0 million","upfrontCash":"$200.0 million","newsHeadline":"AstraZeneca To Acquire Neogene Therapeutics, Accelerating Ambition in Oncology Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"Neogene","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$320.0 million","upfrontCash":"$320.0 million","newsHeadline":"Acquisition of Neogene Therapeutics Completed","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"}]

    Find Clinical Drug Pipeline Developments & Deals by Neogene

    Menu

    Neogene

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Neogene

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              AstraZeneca To Acquire Neogene Therapeutics, Accelerating Ambition in Oncology Cell Therapy

              Details:

              With a shared goal of bringing cell therapies to patients with solid tumours, Neogene’s expertise in TCR-T discovery, development and manufacturing will strengthen AstraZeneca’s ambition to transform outcomes for patients.

              Lead Product(s): TCR Therapy

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: AstraZeneca

              Deal Size: $320.0 million Upfront Cash: $200.0 million

              Deal Type: Acquisition November 29, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Neogene

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Neogene Therapeutics Announces Approval of Clinical Trial Application for its First Phase 1 Trial of Novel, Fully-Individualized TCR Therapy to Treat Advanced Solid Tumors

              Details:

              NT-125, designed to contain up to five distinct neoantigen-specific TCRs per patient in single cell product of highly functional engineered T cells, allowing multiple neoantigens by HLA molecules targeted with goal to create a more impactful TCR therapy for more patients.

              Lead Product(s): NT-125

              Therapeutic Area: Oncology Product Name: NT-125

              Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 10, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Neogene

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Acquisition of Neogene Therapeutics Completed

              Details:

              Acquisition will provide access to next-generation T-cell receptor therapies with promising potential for targeting solid tumours to AstraZeneca. TCR-based Therapies can recognise intracellular targets, including cancer-specific mutations.

              Lead Product(s): TCR-based Therapy

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: AstraZeneca

              Deal Size: $320.0 million Upfront Cash: $320.0 million

              Deal Type: Acquisition January 16, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Neogene

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Twist Bioscience and Neogene Announce Broad Strategic Partnership for Next Generation Personalized T Cell Therapies

              Details:

              The companies will leverage Neogene’s expertise in targeting tumor neo-antigens, mutated proteins found in cancer cells together with Twist’s DNA synthesis platform and product lines to develop personalized CAR) T cell therapies and TCR therapies for patients with cancer.

              Lead Product(s): CAR-T cell therapy

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Cell and Gene therapy

              Recipient: Twist Bioscience

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership October 13, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Neogene

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Neogene Therapeutics Raises $110 Million Series A Financing to Develop Next-Generation Neo-Antigen TCR Therapies

              Details:

              Neogene’s proprietary technology platform identifies specific T cell receptor (TCR) genes from routine tumor samples using state-of-the-art synthetic biology tools.

              Lead Product(s): Neo-Antigen T Cell Receptor

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: EcoR1 Capital

              Deal Size: $110.0 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing September 14, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY